VOR Stock Risk & Deep Value Analysis
Vor Biopharma Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on VOR
We analyzed Vor Biopharma Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VOR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
VOR Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Low-Medium
Market Risk
Medium
About Vor Biopharma Inc (VOR)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$207.13M
VOR Deep Value Analysis
Compare VOR to Similar Stocks
See how Vor Biopharma Inc stacks up against related companies in our head-to-head analysis.
VOR Red Flags & Warning Signs
- âš
Negative or inconclusive clinical trial results for VBP101/VCAR33
- âš
Slower than expected patient enrollment in ongoing trials
- âš
Adverse regulatory feedback or delays in clinical development path
- âš
Need for additional significant financing before projected runway, leading to substantial dilution
Unlock VOR Red Flags & Risk Warnings
Create a free account to see the full analysis
VOR Financial Health Metrics
Market Cap
$207.13M
VOR Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability hinges significantly on successful clinical validation of its 'Mine-Resistantâ„¢' platform, followed by robust patent protection for its gene-edited hematopoietic stem cells (HSPCs) and the combination therapy approach. If VBP101/VCAR33 becomes a standard of care, the regulatory approvals and established clinical efficacy will create high barriers to entry.
VOR Competitive Moat Analysis
Sign up to see competitive advantages
VOR Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early May 2026)
- •Updates on VBP101 and VCAR33 clinical trial enrollment progress
- •Potential initial safety data from VBP101/VCAR33 combination therapy
Medium-Term (6-18 months)
- •Interim clinical data readouts (safety, engraftment, preliminary efficacy signals) for VBP101/VCAR33 combination therapy (mid-late 2026)
- •Potential expansion of clinical trials to additional cohorts or indications
- •Pre-clinical data updates on pipeline assets beyond VOR301
Long-Term (18+ months)
- •Initiation of pivotal clinical trials (Phase 2/3) based on positive Phase 1/2 data
- •Potential strategic partnerships or licensing agreements driven by strong data
- •Establishment of VOR's 'Mine-Resistant™' platform as a new standard of care in targeted cell therapies for blood cancers
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
VOR Bull Case: What Could Go Right
- ✓
Positive safety and efficacy data from VBP101/VCAR33 clinical trials
- ✓
Acceleration in patient enrollment or expansion into new clinical indications
- ✓
Announcements of new strategic partnerships or licensing agreements for platform validation
- ✓
Unexpected cash burn increase or need for further dilutive financing beyond current runway
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
